Navigation Links
Arpida Reports Interim Results For Six Months to 30 June 2009
Date:8/19/2009

REINACH, Switzerland, August 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the six months ending 30 June 2009.

    Key events 2009 to date

    - Regulatory setback for intravenous iclaprim in cSSSI in U.S.A.
    - Strategic options under review
    - Company restructuring completed

Cash and financial investments of CHF 22.7 million at 30 June 2009

CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn. We expect to have cash and financial investments of around CHF 14 million at the end of 2009."

Dr Jurgen Raths, President and CEO, commented: "Arpida is going through challenging times. We've completed a painful restructuring process in anticipation of a possible strategic deal. We remain fully committed to finding a strategic partner and securing the maximum value for our shareholders. Discussions are ongoing, as soon as these advance, we will provide an update."

The full 10 page text is available under: http://www.arpida.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:

    Dr Jurgen Raths, President and CEO
    Tel: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. Arpida to Discuss Strategy With Shareholders
3. Arpida Announces Full Year 2008 Financial Results
4. Arpida to Restructure and Focus on Key Projects
5. Arpidas iclaprim MAA Accepted for Review by EMEA
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
8. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
9. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
10. Arpida Announces Conference Call on 17 April
11. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):